skip to content
 

Seminars (DAEW03)

Videos and presentation materials from other INI events are also available.

Search seminar archive

Date Time Speaker Title Presentation Material
15th August 2011 09:00 to 09:45 V Fedorov Design of clinical trials with multiple end points of different types
15th August 2011 09:45 to 10:30 A Grieve The Role of Operating Characteristic in Assessing Bayesian Designs in Pharmaceutical Drug Development
15th August 2011 11:00 to 11:45 D Berry The Critical Path: "Biomarker Development and Streamlining Clinical Trials"
15th August 2011 11:45 to 12:30 A Atkinson Experiments for Enzyme Kinetic Models
15th August 2011 14:00 to 14:45 A Donner The Role of Cluster Randomization Trials in Health Research
15th August 2011 14:00 to 14:45 J Lee Biomarker-based Bayesian Adaptive Designs for Targeted Agent Development - Implementation and Lessons Learned from the BATTLE Trial
15th August 2011 14:45 to 15:25 M Campbell Cluster Randomised Trials: coping with selective recruitment, baseline covariates and anticipated drop-outs?
15th August 2011 14:45 to 15:25 K Wathen ISPY-2: Adaptive Design to Identify Treatments for Biomarker
15th August 2011 15:25 to 16:05 S Eldridge Sample size calculations for cluster randomised trials
15th August 2011 15:25 to 16:05 T Braun Bayesian Adaptive Designs for Identifying Maximum Tolerated Combinations of Two Agents
15th August 2011 16:35 to 17:15 I White A cluster-randomised cross-over trial
15th August 2011 16:35 to 17:15 B Bogachka Dose Selection Incorporating PK/PD Information in Early Phase Clinical Trials.
15th August 2011 17:15 to 17:55 C Weijer Ethical issues posed by cluster randomized trials in health research
15th August 2011 17:15 to 17:55 K Cheung Objective Calibration of the Bayesian Continual Reassessment Method
16th August 2011 09:30 to 10:00 V Dragalin Adaptive Dose-Ranging Designs with Two Efficacy Endpoints
16th August 2011 10:00 to 10:30 L Pronzato Penalized optimal design for dose finding
16th August 2011 10:30 to 11:00 C Jennison Jointly optimal design of Phase II and Phase III clinical trials: an over-arching approach
16th August 2011 11:30 to 12:00 S-J Wang Utility and pitfals of dose ranging trials with multiple study objectives: fixed or adaptive
16th August 2011 12:00 to 12:30 J Pinheiro Improving dose-finding methods in clinical development: design, adaptation, and modeling
16th August 2011 14:00 to 14:30 F Bretz Response-adaptive dose-finding under model uncertainty
16th August 2011 14:30 to 15:00 H Thygesen Dose Escalation using a Bayesian Model: rational decision rules.
16th August 2011 15:00 to 15:30 B Neuenschwander Bayesian approaches to Phase I clinical trials: methodological and practical aspects
16th August 2011 15:30 to 16:00 S Leonov Application of model-based designs in drug development
16th August 2011 16:45 to 18:00 M Krams Design of Experiments in Healthcare, dose-ranging studies, astrophysics and other dangerous things
17th August 2011 09:00 to 09:45 J Louviere A Brief History of DCEs and Several Important Challenge
17th August 2011 09:45 to 10:30 M Ryan Discrete Choice Experiments in Health Economics
17th August 2011 11:00 to 11:45 J Rose Sample size, statistical power and discrete choice experiments: How much is enough
17th August 2011 11:00 to 11:45 C Taylor Systematic review of the use of stepped wedge cluster randomized trials
17th August 2011 11:45 to 12:30 P Goos Optimal designs for discrete choice experiments in the presence of many attributes
17th August 2011 11:45 to 12:30 L Moulton Challenges in the Design and Analysis of a Randomized, Phased Implementation (Stepped-Wedge) Study in Brazil
17th August 2011 12:30 to 13:00 SG Thompson Stepped wedge randomised trials
17th August 2011 12:30 to 13:00 H Grossmann Partial profile paired comparison designs for avoiding information overload
18th August 2011 09:00 to 09:45 E Lancsar Discrete choice experimental design for alternative specific choice models: an application exploring preferences for drinking water
18th August 2011 09:45 to 10:30 R Kessels The usefulness of Bayesian optimal designs for discrete choice experiments
18th August 2011 11:45 to 12:30 P van de Ven An efficient alternative to the complete matched-pairs design for assessing non-inferiority of a new diagnostic test
18th August 2011 14:00 to 14:45 Y Ji From Bench to Bedside: The Application of Differential Protein Networks on Bayesian Adaptive Designs for Trials with Targetted Therapies
18th August 2011 14:45 to 15:30 K Kim A Bayesian Adaptive Design with Biomarkers for Targeted Therapies and Some Commentary on Adaptive Designs
18th August 2011 16:00 to 16:45 P Thall Optimizing the Concentration and Bolus of a Drug Delivered by Continuous Infusion
18th August 2011 16:45 to 17:30 B Mukherjee Discussion of three talks on (covariate) adaptive designs
19th August 2011 09:45 to 10:30 B Bornkamp Functional uniform prior distributions for nonlinear regression
19th August 2011 11:00 to 11:45 M Savelieva Praz PKPD modelling to optimize dose-escalation trials in Oncology
19th August 2011 11:45 to 12:30 J Taylor Designs and models for Phase I oncology trials with intra-patient dose escalation
19th August 2011 14:00 to 14:45 N Flournoy Some Issues Response-Adaptive Designs for Dose-finding Experiments
19th August 2011 14:45 to 15:30 B Rosenberger Principles for Response-Adaptive Randomization
19th August 2011 15:30 to 16:15 A Giovagnoli Recent developments in adaptive clinical trials to account for individual and collective ethics
University of Cambridge Research Councils UK
    Clay Mathematics Institute The Leverhulme Trust London Mathematical Society Microsoft Research NM Rothschild and Sons